In B-cell malignancies, the role of the BCR signaling pathway was proven in the pathophysiology of CLL (27), Waldenström macroglobulinemia (28), diffuse large B-cell lymphoma of the activated B-cell subtype (DLBCL-ABC) (29), mantle-cell lymphoma (MCL) (30), MZL (31), and more recently HCL and SBLPN. This evidence concerns the gene BCR and hairy cell leukemia.